当前位置: 首页 > 期刊 > 《中国医学创新》 > 2019年第26期
编号:13447546
基于PD-L1阻断的联合免疫治疗在结直肠癌中的应用(6)
http://www.100md.com 2019年9月15日 《中国医学创新》 2019年第26期
     [26] Zelenay S,Vanderveen A,B?ttcher J,et al.Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity[J].Cell,2015,162(6):1257-1270.

    [27]高旭,陈维荣,李彦冲.共刺激分子PD-L1在结肠癌中的表达、意义及其与预后的关系[J].汕头大学医学院学报,2017,30(1):11-14.

    [28] Zitvogel L,Kepp O,Kroemer G.Decoding cell death signals in inflammation and immunity[J].Cell,2010,140(6):798-804.

    [29] Shalapour S,Fontburgada J,Di C G,et al.Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy[J].Nature,2015,521(7550):94-98.

    [30] Viaud S,Saccheri F,Mignot G,et al.The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide[J].Science,2013,342(6161):971-976.

    [31] Iida N,Dzutsev A,Stewart C A,et al.Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment[J].Science,2013,342(6161):967-970.

    [32] Vétizou M,Pitt J M,Daillére R,et al.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota[J].Science,2015,350(6264):1079-1084.

    (收稿日期:2019-02-19) (本文編辑:张爽), http://www.100md.com(陈一林)
上一页1 2 3 4 5 6